Relmada Therapeutics, Inc. RLMD
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Relmada Therapeutics, Inc. (RLMD) is a healthcare company listed in the US with a market value of about $449M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -95%.
About Relmada Therapeutics
Relmada Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 33% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$57M | -$80M | -$99M | -$157M | -$126M | -$59M | -$15M | -$9M | -$6M | -$3M |
| Free cash flow | — | — | — | — | — | -$210M | -$97M | -$6M | -$7M | -$14M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 | $-3.81 | $-1.62 | $-2.86 | $-2.08 | $-1.04 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -54.0% | -186.6% | -96.0% | -90.7% | -47.7% | -45.5% | -10.3% | — | -328.3% | -175.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $10.75, 155% above the current price; targets range from $9.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.41 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Relmada Therapeutics pay a dividend?
Not currently.
Is Relmada Therapeutics a good stock to buy?
We do not give buy or sell advice. Relmada Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.